Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
August 28, 2006
- NEW PRODUCTS
August 28, 2006
- COMMENTARY／Korosho Gets Involved to Eliminate Provisional Delivery
August 28, 2006
- Drug Development Beyond Borders -Today's Global Cooperative Clinical Trials-
August 28, 2006
- Drug Firms Should Support Job Sharing between Regional Med. Institutions: Mr Matsubara
August 28, 2006
- Use of Generic Drugs Increasing at Tokyo Municipal Hospitals
August 28, 2006
- Drug Makers Actively Outsourcing to India: MediBic
August 28, 2006
- Doctors Object to Generics Use Promotion Service
August 28, 2006
- Drug Development Beyond Borders -Today's Global Cooperative Clinical Trials-
August 21, 2006
- JMA Demands Elimination of Losses Related to Consumption Tax
August 21, 2006
- OPINION／The Power of Positive People
August 21, 2006
- SJP to Organize Periodical Seminars on Regulatory Affairs
August 21, 2006
- MEDICAL DEVICE NEWS IN BRIEF
August 21, 2006
- REGULATORY NEWS IN BRIEF
August 21, 2006
- Gov't-Administered Health Insurance to Return to Deficit in FY2006
August 21, 2006
- SELF-MEDICATION NEWS IN BRIEF
August 21, 2006
- Kenporen Member Societies Report Surplus 3 Years in a Row in FY2005
August 21, 2006
- New Antibody Manufacturing Technology Established: Chiome Bioscience
August 21, 2006
- Korosho to Review Its Gastric Cancer Detection Program
August 21, 2006
- SymBio Initiates PI Clinical Trial of Bendamustine
August 21, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…